SCHEMBL831663

SCHEMBL831663

Cc1ccc(-c2c(C(=O)NS(=O)(=O)C3CC3)n(Cc3cc4ccccc4nc3Cl)c3cc(F)c(C)cc23)c(=O)[nH]1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C8 P10632 1/20 0.60
SCN9A Q15858 11/20 0.33
PTGER4 P35408 1/20 0.32
FAAH O00519 1/20 0.32
SCN5A Q14524 7/20 0.32
SCN1A P35498 4/20 0.32
SCN4A P35499 2/20 0.32
SCN7A Q01118 1/20 0.32
SCN2A Q99250 1/20 0.32
SCN3A Q9NY46 1/20 0.32
SCN8A Q9UQD0 1/20 0.32
SCN2B O60939 4/20 0.32
SCN1B Q07699 4/20 0.32
TRPM4 Q8TD43 1/20 0.32
AURKA O14965 1/20 0.31
TPX2 Q9ULW0 1/20 0.31
CYP2C9 P11712 1/20 0.31
MOGAT2 Q3SYC2 1/20 0.31
RAB9A P51151 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL833375 0.93 CYP2C8 (0.59) CYP2C8FAAHRAB9ASMN1; SMN2HDAC3
SCHEMBL831646 0.91 CYP2C8 (0.74) CYP2C8SCN9APTGER4FAAHSCN5A
SCHEMBL831650 0.84 CYP2C8 (0.65) CYP2C8SCN9APTGER4FAAHSCN5A
SCHEMBL862278 0.84 CYP2C8 (0.64) CYP2C8SCN9APTGER4FAAHSCN5A
SCHEMBL13905194 0.82 CYP2C8 (0.61) CYP2C8SCN9ASCN5AAURKATPX2
SCHEMBL832872 0.81 CYP2C8 (0.60) CYP2C8SCN9AFAAHSCN5ASCN1A
SCHEMBL832191 0.81 CYP2C8 (0.51) CYP2C8SCN9APTGER4
SCHEMBL831122 0.81 CYP2C8 (0.59) CYP2C8SCN9APTGER4FAAHSCN1A
SCHEMBL8859126 0.81 CYP2C8 (0.60) CYP2C8SCN9ASCN5ASCN1ASCN4A
SCHEMBL832172 0.80 CYP2C8 (0.76) CYP2C8SCN9AAURKATPX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2197842-B1 2, 3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS SCHERING CORP (US) 2012-05-23 EP disclosed
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 US disclosed
US-8143305-B2 2,3-substituted indole derivatives for treating viral infections SCHERING CORPORATION (US) 2012-03-27 US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 US disclosed
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS MERCK SHARP & DOHME CORP. 2011-02-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110033417-A1 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS IDO2, IDO1, IRF3 CYP2C8 847/4885SCN9A 3807/4885PTGER4 2953/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.